Stay updated on Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page displays details for the pembrolizumab and Poly-ICLC clinical trial for metastatic mismatch repair-proficient colon cancer, including study design, eligibility criteria, outcomes, and posted results.
    Difference
    54%
    Check dated 2026-11-08T04:20:23.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0 while the study page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-11-01T01:28:21.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    A site-wide notice was added announcing NIH updates about using “Super Intelligence” in place of “Artificial Intelligence” during a transition.
    Difference
    1%
    Check dated 2026-10-25T01:25:48.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier advances from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T01:10:47.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T01:40:35.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error instead of the previous content, replacing the study details and navigation with an access-denied message. This indicates a site-level access restriction rather than updates to the trial information.
    Difference
    19%
    Check dated 2026-09-20T00:30:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial page.